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Abstract : To evaluate prognostic factors for recurrence after tegafur-uracil plus 
leucovorin （UFT / LV） adjuvant chemotherapy in patients with colorectal cancer 
（CRC）.  Consecutive patients with CRC who received UFT / LV as adjuvant che-
motherapy at Showa University Hospital between June 2005 and December 2008 
were included in the study, 5-year disease-free survival （DFS） and overall survival 
（OS） rates were estimated, and prognostic factors for recurrence were analyzed 
using the Cox proportional hazards model for multivariate analysis.  Of 92 patients 
included in the study, 17 （18.5％） had disease recurrence.  The 5-year DFS and OS 
rates were 82.2％ and 91.9％, respectively.  In the multivariate analysis, preoperative 
CA19-9 level ＞ 37 U / ml, emergency operation, and T4 lesions were independent 
signicant prognostic factors after treatment with UFT / LV adjuvant chemotherapy.  
The three independent prognostic factors ― T4 lesions, emergency operation, and 
high preoperative CA19-9 levels― may be useful for decision-making regarding 
whether patients should receive 5-fluouracil-based or L-oxaliplatin-based adjuvant 
chemotherapy.  As this was a single-institution study with a small number of 
patients, our ndings need to be conrmed in larger multicenter studies..
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Introduction
　In patients with cancer, postoperative adjuvant chemotherapy reduces disease recurrence and 
improves overall survival.  Such benefits for patients with Stage Ⅲ colorectal cancer （CRC） are 
great enough to recommend adjuvant chemotherapy1）.  Based on the results from the Japan 
Clinical Oncology Group （JCOG0205）2） and the National Surgical Adjuvant Breast and Bowel 
Protocol （NSABP C-06）3）, a regimen of uracil and tegafur plus leucovorin （UFT / LV） has been 
widely used as standard postoperative adjuvant chemotherapy for Stage Ⅲ CRC in Japan.
　L-oxaliplatin （L-OHP）-based adjuvant chemotherapy such as FOLFOX （oxaliplatin plus 
infusional leucovorin and fluorouracil）4） and 5-fluouracil （5-FU）-based adjuvant chemotherapy 
such as capcitabine 5） or 5-FU / LV are also used as standard adjuvant chemotherapy for Stage Ⅲ 
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CRC in Japan 6）.  Furthermore, based on the results of the Adjuvant Chemotherapy Trial of TS-1 
for Colon Cancer （ACTS-CC） trial 7）, which demonstrated non-inferiority of S-1 compared with 
UFT / LV for Stage Ⅲ colon cancer, S-1 will also be a new adjuvant chemotherapy option for 
colon cancer.  However, clinically useful predictors that can help select adjuvant chemotherapy 
regimens have not been identified.  Although various findings in patients with Stage Ⅱ CRC, 
including poorly differentiated histology, T4 lesions, perforation, and inadequately sampled lymph 
nodes （n＜13）, have been considered for use in selection of adjuvant chemotherapy 8-10）, there is 
no international consensus.  Therefore, we evaluated long-term outcomes and prognostic factors 
for recurrence after UFT / LV adjuvant chemotherapy in patients with Stage Ⅱ or Ⅲ CRC and 
identified potential selection criteria for UFT / LV as adjuvant chemotherapy.
Materials and methods
Patients
　From June 2005 to December 2008, consecutive patients who received oral UFT / LV 
as adjuvant chemotherapy only for CRC at Showa University Hospital were prospectively 
enrolled.  The main inclusion criteria for treatment with UFT / LV adjuvant chemotherapy were :  
histologically proven Stage Ⅱ or Ⅲ colorectal adenocarcinoma, an Eastern Cooperative Oncology 
Group performance status （PS） of 1, no prior chemotherapy or radiotherapy for CRC, and 
adequate bone marrow, renal and hepatic function.
　This study was conducted in accordance with the Declaration of Helsinki.  Written informed 
consent was obtained from all patients, with the approval of the ethics committee of Showa 
University Hospital.
Treatment protocol
　We administered chemotherapy to all eligible patients between 3 and 6 weeks after surgery. 
UFT （300 mg / m2 / day） and LV （75 mg / body / day） were administered orally on days 1—28, 
followed by a 7-day rest period ; this 35-day cycle was repeated up to five times.  The daily 
UFT and LV doses were divided into three doses that were given 8 h apart with water. 
Patients were instructed to avoid consuming food during the hour before and the hour after 
each dose.  Additional details and toxicity assessments have been described elsewhere 11）.
Patient follow-up and recurrence of disease
　After completing chemotherapy, patients were scheduled for follow-up as outpatients every 3 
months during the first 3 years, every 6 months during the next 2 years, and annually thereafter, 
as per the 2010 Japanese Society for Cancer of the Colon and Rectum （JSCCR） guidelines 6）. 
Levels of serum tumor markers （carcinoembryonic antigen ［CEA］ and carbohydrate antigen 
19-9 ［CA19-9］） were measured every 3 months for the first 3 years and every 6 months for 
the next 2 years.  Computed tomography （CT） scans of the chest, abdomen, and pelvis were 
performed every 6 months for 5 years.  Colonoscopies were performed every 12 months for 3 
years.
21Relapse Factors after UFT / LV Adjuvant for CRC
　Local recurrence was defined as clinical or radiologic tumor regrowth within the previous 
pelvic treatment field, peritoneum, or anastomosis.  Distant recurrence was defined as tumor 
growth in any other area.  Overall survival （OS） was calculated from the date of surgery to the 
date of death or last follow-up.  Disease-free survival （DFS） was defined as the period from the 
date of surgery to the date of recurrence or last follow-up.
Clinical and pathological variables
　The patient characteristics that we recorded included age, sex, PS, tumor location, preoperative 
CEA and CA19-9 levels, histologic type, tumor size, depth of tumor, lymphatic and venous 
invasion, number of lymph node （LN） metastases, degree of LN metastases, pathological 
stage, surgical approach and procedure, level of LN dissection, number of LNs examined, and 
postoperative complications.  DFS, OS, and the relationship between clinicopathological variables 
and development of recurrence were analyzed.  The level of LN dissection and histologic types 
were evaluated according to the Japanese Classification of Colorectal Carcinoma, Second English 
Edition 12）.  Depth of tumor, degree of LN metastases, and pathological stage were categorized 
according to the Seventh Edition of the TNM Classification （TNM7th）13）.
Statistical analysis
　Continuous variables are expressed as medians and ranges.  Categorical variables are expressed 
as numbers and percentages.  The relationship between clinicopathological variables and 
development of recurrence were assessed by univariate analyses using Cox proportional hazards 
regression models and are expressed as hazard ratios and 95％ confidence intervals （CIs）.  All 
factors with a p value of ＜0.05 were introduced into multivariate Cox regression analyses with 
a semi-manual backward （likelihood ratio） variable selection.  The 5-year DFS and OS rates 
were estimated using the Kaplan—Meier method.  Finally, based on the number of prognostic 
factors for recurrence, DFS and OS were compared using a log-rank test and Wilcoxon test.  All 
statistical analyses were performed using JMPⓇ Pro version 11.0.0 software （SAS Institute, Cary, 
NC, USA） and p values of ＜ 0.05 were considered statistically significant.
Results
Patient characteristics and surgical outcomes
　A total of 92 patients were enrolled in the study.  Patient characteristics and surgical outcomes 
are summarized in Table 1.  Emergency operations were performed for two patients （2.2％） due 
to tumor perforation.
Evolution of disease
　The median follow-up period was 70 months （range, 9—120 months）.  Seventeen patients 
（18.5％） developed disease recurrence ; their characteristics are listed in Table 2.  Eight of 
them （47.1％） had local recurrence （median time to relapse, 23.3 months） ― three developed 
peritoneal recurrences, and five developed anastomotic recurrences.  The other nine （52.9％） 
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developed distant recurrences （median time to relapse, 15.1 months）― three, three, two and one 
developed metastases of the liver, lungs, distant lymph nodes, and omentum, respectively.  When 
recurrences were categorized according to stage （TNM7th）, four patients （23.5％） were in stage 
ⅡA, two （11.8％） were in ⅡB, three （17.6％） were in ⅡC, two （11.8％） were in ⅢA, four 
（23.5％） were in ⅢB, and two （11.8％） were in ⅢC.
　As the first treatment for recurrence, eight patients underwent an operation, five patients 
received L-OHP-based adjuvant chemotherapy such as FOLFOX or CPT-11 plus infusional 
leucovorin and fluorouracil （FOLFIRI）, three patients received S-1 plus CPT-11, and one patient 
received best supportive care.  At last follow-up, five patients were still receiving chemotherapy. 
Age （years） Median （range） 67 （30-84）
Sex M / F 60 / 32
PS （ECOG）, N （％） 0 70 （76.1）
1 22（23.9）
Tumor location, N （％） Right-side colon （C, A, T） 29 （31.5）
Left-side colon （D, S） 27 （29.3）
Rectum 36 （39.1）
Preoperative CEA level （ng / ml）, N （％） 5.1 45 （48.9）
＞ 5.1 32 （34.8）
Unknown 15 （16.3）
Preoperative CA19-9 level （U / ml）, N （％） 37 66 （71.7）
＞ 37  9  （9.8）
Unknown 17 （18.5）
Histologic types a, N （％） Papillaly  1  （1.1）
Tublar 82 （89.1）
poorly  6  （6.5）
Mucinous  3  （3.3）
Tumor size （mm） Median （range） 45 （17-90）
Depth of tumor （TNM 7th）, N （％） T1  1  （1.1）
T2  5  （5.4）
T3 63 （68.5）
T4a 14 （15.2）
T4b  9  （9.8）
Lymphatic invasion, N （％） Negative 21 （22.8）
Positive 71 （77.2）
Venous invasion, N （％） Negative 15 （16.3）
Positiv 77 （83.7）
No. of LN metastases, （N） Median （range）  0 （0-7）
LN metastasis （TNM 7th）, N （％） N0 52 （56.5）
N1a 23 （25.0）
N1b 13 （14.1）
N2a  3  （3.3）
N2b  1  （1.1）
Stage （TNM7th）, N （％） ⅡA 43 （46.7）
Ⅱ B  4  （4.4）
Ⅱ C  5  （5.4）
ⅢA 12 （13.0）
Ⅲ B 22 （23.9）
Ⅲ C  6  （6.5）
Operation, N （％） Elective 90 （97.8）
Emergency  2  （2.2）
Surgical approach, N （％） Laparoscopic 40 （43.5）
Laparotomy 52 （56.5）
Surgical procedure, N （％） Colectomy 57 （62.0）
HAR 11 （11.9）
LAR 11 （11.9）
uLAR  7  （7.6）
Hartmann  1  （1.1）
APR  5  （5.4）
Level of LN dissectiona, N （％） D1  2  （2.2）
D2 36 （39.1）
D3 54 （58.7）
No. of LNs examined, （N） Median （range） 20 （4-52）
Operating time （min） Median （range） 200 （95-735）
Operative blood loss （ml） Median （range） 120 （3-1070）
Complications, N （％） None 70（76.1）
Superficial SSI  7  （7.6）
Organ / space SSI  2  （2.2）
Paralytic ileus 11（11.9）
Remote infections  2  （2.2）
Length of hospital stay （day） Median （range） 11 （4-51）
Remote infections were pneumonia and a urinary tract infection
PS Peformance status, ECOG Eastern Cooperative Oncology 
Group,
C Cecum, A Ascending colon, T Transverse colon, D Descending 
colon, S Sigmoid colon
CEA Carcinoembryonic antigen, CA19-9 Carbohydrate antigen 19-9
HAR High anterior resection, LAR Low anterior resection,
uLAR Ultra-low anterior resection, APR Abdominoperineal 
resection,
LN Lymph node, SSI Surgical site infection
a Japanese Classification of Colorectal Carcinoma, Second English 
Edition （12）
Table 1.　Patient characteristics and surgical outcomes （N＝ 92）
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At the time of the final analysis, eight patients （8.7％） had died due to disease progression. 
The 5-year DFS and OS rates for the entire study population were 82.2％ and 91.9％, 
respectively （Fig. 1a, b）.
Table 2.　Characteristics of patients with disease recurrence









No. of LNs 
examined （N） Site of recurrence
1 Male 71 A Elective tubular T3 IIa 10 Lung
2 Female 52 A Emergency tubular T4b IIc 25 Anastomosis
3 Female 55 S Emergency tubular T4a IIIb  4 Cervical lymph node
4 Female 70 S Elective tubular T4b IIIc  8 Liver
5 Male 76 A Elective tubular T4b IIc 41 Anastomosis
6 Female 56 D Elective tubular T3 IIa  9 Lung
7 Male 62 D Elective tubular T3 IIa  5 Omentum
8 Female 80 C Elective tubular T4b IIIc 22 Peritoneum
9 Female 77 RS Elective tubular T3 IIIb 17 Liver
10 Male 73 D Elective tubular T4a IIb 11 Anastomosis
11 Female 54 Rb Elective tubular T3 IIa 20 Lung
12 Male 65 Ra Elective tubular T4a IIIa 12 Peritoneum
13 Male 58 Rb Elective tubular T3 IIIa 28 Anastomosis
14 Male 49 C Elective mucinous T4a IIb 50 Mediastinal lymph node
15 Male 64 C Elective tubular T4a IIIb 24 Liver
16 Male 73 S Elective tubular T4b IIc 12 Anastomosis









1 Operation→ S-1 / CPT11→Bev. / FOLFOX→Operation→Bev. / FOLFIRI→BSC 15.1 90 Unknown
2 FOLFOX→ BSC 6.8 12 Death
3 Bev.FOLFIRI（Ongoing） 78 114 Survival
4 Operation→ Bev. / FOLFIRI→ BSC 6.8 53 Death
5 Operation→ BSC 17 31 Death
6 Operation→ Bev. / FOLFOX→ BevFOLFIRI→ Cetuximab（Ongoing） 36.5 98 Survival
7 Operation→ Bev. / FOLFOX→ Bev. / FOLFIRI→ Cetuximab（Ongoing） 27.3 96 Survival
8 Not chemotherapy（BSC） 26.7 43 Death
9 Operation 8 50 Unknown
10 Operation→ Lung metastasis→ BSC 35.5 87 Death
11 S-1 / CPT-11→ Bev FOLFOX （Ongoing） 15.1 90 Survival
12 Bev. / FOLFOX→ Bev. / FOLFORI→ BSC 24.2 38 Death
13 FOLFOX→ FOLFIRI 22.3 64 Unknown
14 S-1 / CPT-11→ Bev. / Xelox→ Cetuximab / CPT-11→ BSC 12 38 Death
15 S-1 / CPT-11→ Bev. / FOLFOX→ BSC 11 22 Death
16 Operation→ Capecitabine （Ongoing） 22.1 80 Survival
17 Bev. / FOLFOX→ BSC 26.3 53 Unknown
A Ascending colon, S Sigmoid colon, D Descending colon, RS Rectosigmoid, Ra Rectum （above the peritoneal reection）, Rb 
Rectum （below the peritoneal reection）, M Months, FOLFOX Oxaliplatin plus infusional leucovorin and uorouracil, FOLFIRI 
CPT-11 plus infusional leucovorin and uorouracil, Bev. Bevacizumab, BSC Best supportive care
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Prognostic factors for recurrence
　Results of the univariate and multivariate analyses using the Cox proportional hazard model to 
identify significant prognostic factors for recurrence are presented in Table 3.  In the univariate 
analysis, five variables were identified as significant prognostic factors for recurrence affecting 
DFS : preoperative CA19-9 level ＞ 37 U / ml （hazard ratio ［HR］, 6.520 ; 95％ CI, 1.961—19.650 ; 
p＝0.0036）, emergency operation （HR, 8.978 ; 95％ CI, 1.404—32.284 ; p＝0.025）, D1 LN dissection 
（HR, 6.977 ; 95％ CI, 1.093—25.034 ; p ＝ 0.042）, T4 lesions （HR, 7.553 ; 95％ CI, 2.860—22.015 ; 
p＜0.0001）, and ＞3 LN metastases （HR, 5.661 ; 95％ CI, 1.296—17.570 ; p ＝ 0.025）.  In the 
multivariate analysis, preoperative CA19-9 level ＞ 37 U / ml （HR, 7.826 ; 95％ CI, 1.562—33.271 ; 
p＝ 0.016）, emergency operation （HR, 3.560e＋9 ; 95％ CI, 1.323—1.164e＋ 20 ; p＝ 0.038）, and 
T4 lesions （HR, 5.571 ; 95％ CI, 1.472—22.184 ; p＝ 0.012） were independent significant prognostic 
factors after treatment.  Both DFS and OS were significantly different according to the number 
of independent prognostic factors for recurrence （number of prognostic factors 0 vs 1 : HR, 
Fig. 1.  Disease-free survival （DFS） and overall survival （OS） curves for all patients and 
for patients in Stage Ⅱ and Ⅲ.
（a） DFS curve for all patients ; the 5-year DFS rate was 82.2％.
（b） OS curve for all patients ; the 5-year OS rate was 91.9％.
（c） DFS curves for Stage Ⅱ and Stage Ⅲ patients ; the 5-year DFS rates for Stage Ⅱ 
and Stage Ⅲ patients were 82.5％ and 81.9％, respectively. There was no significant 
difference in 5-year DFS between Stage Ⅱ and Stage Ⅲ patients （log-rank test ; p＝
0.696）.
（d） OS curves for Stage Ⅱ and Stage Ⅲ patients ; the 5-year OS rates for Stage Ⅱ and 
Stage Ⅲ patients were 94.7％ and 89.1％, respectively. There was no significant 
difference in 5-year OS between Stage Ⅱ and Stage Ⅲ patients （log-rank test ; p＝
0.674）.
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Table 3.　 Univariate and multivariate analyses using the Cox proportional hazard model to identify 
signicant prognostic factors for recurrence
Univariate analysis Multivariate analysis
Factor Hazard ratio （95％ CI） P value Hazard ratio （95％ CI） P value
Age （years）
＞ 65 0.639 （0.232-1.667） 0.36
65 1
Sex
Male 0.584 （0.223-1.556） 0.274
Female 1
Preoperative CEA level （ng / ml）
＞ 5.1 1.312 （0.422-3.952） 0.627
5.1 1
Preoperative CA19-9 level （U / ml）
＞ 37 6.520 （1.961-19.650） 0.0036 11.038 （2.517-47.262） 0.0025
37 1 1
Operation
Emergency 8.978 （1.404-32.284） 0.025 15.002 （1.732-101.219） 0.017
Elective 1 1
Tumor location
Colon 2.561 （0.905-9.102） 0.078
Rectum 1
Surgical approach
Laparotomy 1.792 （0.663-6.640） 0.258
Laparoscopic 1
Tumor size
＞ 50 0.783 （0.284-2.040） 0.618
50 1
LN dissection
D1 6.977 （1.093-25.034） 0.042 2.058 （0.088-23.763） 0.592
D2, D3 1 1
Histologic types
Mucinous, poorly 1.695 （0.266-6.070） 0.513
Tubular, Papirally 1
Depth of tumor
T4 7.553 （2.860-22.015） ＜0.0001 4.956 （1.172-21.230） 0.03
T3 1 1
Lymphatic invasion
Positive 1.053 （0.297-2.977） 0.928
Negative 1
Venous invasion
Positive 1.539 （0.434-9.767） 0.545
Negative 1
No.  of LNs examined
＞ 13 1.952 （0.733-5.107） 0.175
13 1
No.  of LN metastases
＞ 3 5.661 （1.296-17.570） 0.025 4.101 （0.572-19.610） 0.14
3 1 1
Stage
Ⅱ 1.208 （0.453-3.162） 0.698
Ⅲ 1
Postoperative complications
＋ 1.948 （0.676-5.131） 0.207
- 1
CEA Carcinoembryonic antigen, CA19-9 Carbohydrate antigen 19-9
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6.976 ; 95％ CI, 2.580—21.973 ; log-rank test, p＜ 0.0001 ; Wilcoxon test, p＜ 0.0001） （Fig. 2）.
Discussion
　To our knowledge, this is the first report on the analysis of prognostic factors for recurrence 
after UFT / LV adjuvant chemotherapy for patients with CRC.  In this study, common sites of 
recurrence after UFT / LV adjuvant chemotherapy included the anastomosis （29.4％ ［5 / 17］）, 
and other local sites, the liver and the lungs （17.6％ ［3 / 17］ each）.  According to the JSCCR, 
the recurrence rates after curative resection are 2.4％ for the anastomosis, 23.1％ for other local 
Fig. 2.  Disease-free survival （DFS） and overall survival （OS） 
curves based on the number of prognostic factors for 
recurrence.＊
（a） DFS curves based on the number of prognostic factors for 
recurrence
（b） OS curves based on the number of prognostic factors for 
recurrence
＊ Number of prognostic factors 0 vs 1 : hazard ratio, 6.976 ; 
95％ CI, 2.580—21.973 ; log-rank test, p＜0.0001 ; Wilcoxon 
test, p＜0.0001.
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sites, 41.2％ for the liver, 27.6％ for the lungs, and 22.0％ for other sites （including overlaps）6）. 
Although it is not possible to directly compare recurrence patterns, they may have been affected 
by UFT / LV adjuvant chemotherapy ; in particular, hematogenous metastases such as liver and 
lung metastases may have been suppressed by UFT / LV.
　In NSABP C-06, which evaluated the non-inferiority of UFT / LV compared with intravenous 
5-FU / levofolinate （l-LV） as adjuvant chemotherapy in Stage Ⅱ and Ⅲ colon cancer, the 5-year 
DFS rate was 67.0％3）.  Conversely, in JCOG0205, which also evaluated the non-inferiority of 
UFT / LV compared with 5FU / l-LV in Stage Ⅲ CRC, the 5-year DFS rate was 73.6％.  In 
our study, the 5-year DFS rate was 82.2％ for all patients and 81.9％ for patients in Stage Ⅲ 
（Fig. 1c）2）.  The 5-year OS rate for patients in Stage Ⅲ in our study was 89.1％ （Fig. 1d）, 
which was similar to the 87.5％ in the JCOG0205 trial.  In our study, 16 of the 17 patients who 
had recurrence underwent surgery or systemic chemotherapy for recurrence, and five received 
L-OHP- or 5FU-based chemotherapy during progression-free survival.  Thus, in addition to the 
UFT / LV adjuvant chemotherapy, surgery and novel anticancer agents may have contributed to 
the remarkable improvement in the 5-year OS.
　The pathological stage of T4 and intestinal perforation can identify a minority of Stage Ⅱ 
CRC patients who have a higher risk of recurrence8-10）.  Of the 17 patients who had recurrence 
after UFT / LV adjuvant chemotherapy in our study, nine were in Stage Ⅱ （Table 2）.  Of them, 
five had T4 lesions, and three had ＜13 sampled LNs.  This meant that eight of the nine Stage 
Ⅱ patients who had recurrence （88.9％） had high-risk Stage Ⅱ disease.  Therefore, aggressive 
adjuvant chemotherapy should given to patients with CRC who are in Stage Ⅲ and to a 
minority of those in high-risk Stage Ⅱ.
　Serum CEA levels have been shown to be elevated in a majority of patients with recurrence 
after curative resection for CRC 14）.  In particular, 80％ of patients with hepatic recurrence had 
elevated serum CEA levels.  In this study, the preoperative CEA level was not a significant 
prognostic factor for recurrence after UFT / LV adjuvant chemotherapy in the univariate analysis. 
The UFT / LV adjuvant chemotherapy may have suppressed hematogenous metastases such as 
liver and lung metastases ; as a result, preoperative CEA level was not selected as a prognostic 
factor for recurrence.  Although the American Society of Clinical Oncology guidelines for the 
use of tumor markers in CRC state that there are insufficient data to recommend CA19-9 for 
screening, diagnosis, staging, surveillance, or treatment monitoring in CRC 15）, CA19-9 has been 
widely used as a tumor marker for CRC.  Takakura et al reported that the preoperative CA19-
9 level was a significant predictor of peritoneal dissemination and poor survival in patients 
with CRC 16）.  Furthermore, Nakagoe et al reported that the preoperative CA19-9 level might 
serve as a useful marker in identifying node-negative CRC patients who are at high risk of 
recurrence after surgery 17）.  Since recurrence patterns may have changed with UFT / LV adjuvant 
chemotherapy and the rate of peritoneal recurrence was high, we selected the preoperative 
CA19-9 level （which is a significant predictor of peritoneum recurrence） as an independent 
prognostic factor for recurrence.
　The 5-year DFS and OS rates for patients who had at least one of the independent 
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prognostic factors （T4 lesions, emergency operation, and high preoperative CA19-9 level） 
were significantly worse than those for patients who did not have any of these three factors. 
Therefore, Stage Ⅲ or high-risk Stage Ⅱ CRC patients with none of the three independent 
prognostic factors may be suitable for oral 5-FU-based adjuvant chemotherapy.  Stage Ⅲ or high-
risk Stage Ⅱ patients who have any one of three independent prognostic factors should receive 
another recommended adjuvant therapy, such as L-OHP-based chemotherapy, because they have 
a very high likelihood of recurrence.
　Several limitations to our study must be considered.  First, the number of patients was small. 
This meant that while emergency operation was selected as an independent prognostic factor, 
only two patients had emergency operations in our study.  Therefore, type I errors could not be 
avoided when analyzing prognostic factors for recurrence.  However, CRC with perforation was 
not found to be an independent prognostic factor in our study, although it has previously been 
shown to be a risk factor for recurrence and to indicate poor prognosis 18-20）, so it must be an 
important prognostic factor.  Second, we conducted a retrospective study at a single institution, 
not a prospective study that compared CRC patients with and without adjuvant therapy.  Third, 
our study did not include the biomarkers associated with CRC recurrence or molecular markers 
associated with response to anticancer agents.  Several molecular markers have been shown 
to be satisfactory predictors of the efficacy of 5-FU-based or L-OHP-based chemotherapy 21-27）. 
Yothers et al reported that the 12-gene Recurrence Score provides additional information beyond 
the conventional clinical and pathological factors 28）; this score is a predictor of recurrence 
risk that was developed using gene expression data 29）.  In clinical practice, these factors could 
improve decision-making regarding adjuvant chemotherapy for patients with Stage Ⅱ and Ⅲ 
colon cancer.
　In conclusion, for patients with CRC who receive UFT / LV adjuvant chemotherapy, three 
independent prognostic factors― T4 lesions, emergency operation, and a high preoperative CA19-
9 level―may be useful for decision-making regarding the choice between 5-FU-based and 
L-OHP-based adjuvant chemotherapy.
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